Estimating the global and regional impact of introducing typhoid conjugate vaccination schedules: a modelling study

BACKGROUND: In 2018, WHO recommended single-dose typhoid conjugate vaccines (TCVs) for typhoid-endemic countries. Emerging evidence of waning immunity has raised questions about optimal vaccination age and booster doses. A follow-up multi-model study evaluated vaccination schedules, focusing on booster strategies. Here, we expand findings from one of four modelling groups, estimating the global and regional health impact of TCV schedules. METHODOLOGY: We developed an agent-based typhoid transmission model using the open-source Starsim toolbox. The model captures subclinical and acute infections, chronic carriers, and natural and vaccine-derived immunity, with age- and sex-specific parameters and outcomes. The model was calibrated to three incidence archetypes (medium, high, and very high) and two vaccine-derived immunity durations (fast and slow waning). Countries were mapped to archetypes based on national typhoid burden. We compared no vaccination with four strategies: routine vaccination at 9 months, 9 months with a booster at 5 years, 2 years, and 5 years, each with a catch-up campaign. Cases, deaths, and DALYs averted were estimated globally and across GBD super-regions over 10 years. RESULTS: Globally, up to 29.5 million cases and 8.2 million DALYs could be averted with routine vaccination at 9 months plus a 5-year booster. Earlier vaccination and longer-lasting immunity generally increased impact. Under fast waning, vaccination at 2 years averted more cases and DALYs than vaccination at 9 months or 5 years, particularly in high-incidence settings where burden was greatest among children aged 2-<5 years. Boosters provided additional benefits, especially with fast waning. South Asia accounted for the largest share of global impact, followed by Sub-Saharan Africa. CONCLUSION: TCV could avert substantial typhoid burden. The optimal age for a single dose depends on how quickly protection wanes, and boosters add benefit where waning is rapid. Better evidence on the protection duration, and country-specific analyses, are needed to guide schedule choices.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2026-11-17
DOI
https://doi.org/10.1016/j.vaccine.2026.129352
Primary Topic
Salmonella and Campylobacter epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Estimating the global and regional impact of introducing typhoid conjugate vaccination schedules: a modelling study

Nick Scott, Romesh Abeysuriya, Alina M. Muellenmeister
2 links
Vaccine
Salmonella and Campylobacter epidemiology
article

Estimating the global and regional impact of introducing typhoid conjugate vaccination schedules: a modelling study

Nick Scott, Romesh Abeysuriya, Alina M. Muellenmeister
article en

Abstract

BACKGROUND: In 2018, WHO recommended single-dose typhoid conjugate vaccines (TCVs) for typhoid-endemic countries. Emerging evidence of waning immunity has raised questions about optimal vaccination age and booster doses. A follow-up multi-model study evaluated vaccination schedules, focusing on booster strategies. Here, we expand findings from one of four modelling groups, estimating the global and regional health impact of TCV schedules. METHODOLOGY: We developed an agent-based typhoid transmission model using the open-source Starsim toolbox. The model captures subclinical and acute infections, chronic carriers, and natural and vaccine-derived immunity, with age- and sex-specific parameters and outcomes. The model was calibrated to three incidence archetypes (medium, high, and very high) and two vaccine-derived immunity durations (fast and slow waning). Countries were mapped to archetypes based on national typhoid burden. We compared no vaccination with four strategies: routine vaccination at 9 months, 9 months with a booster at 5 years, 2 years, and 5 years, each with a catch-up campaign. Cases, deaths, and DALYs averted were estimated globally and across GBD super-regions over 10 years. RESULTS: Globally, up to 29.5 million cases and 8.2 million DALYs could be averted with routine vaccination at 9 months plus a 5-year booster. Earlier vaccination and longer-lasting immunity generally increased impact. Under fast waning, vaccination at 2 years averted more cases and DALYs than vaccination at 9 months or 5 years, particularly in high-incidence settings where burden was greatest among children aged 2-<5 years. Boosters provided additional benefits, especially with fast waning. South Asia accounted for the largest share of global impact, followed by Sub-Saharan Africa. CONCLUSION: TCV could avert substantial typhoid burden. The optimal age for a single dose depends on how quickly protection wanes, and boosters add benefit where waning is rapid. Better evidence on the protection duration, and country-specific analyses, are needed to guide schedule choices.

VaccineVol. 96
Burnet Institute (AU)
Good health and well-being
Salmonella and Campylobacter epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon